Editorial companion

What stands out

Bloomberg flagged two headline moves: Intel announced a $15 billion common stock offering as it leans into the artificial intelligence (AI) data-center boom, and Moderna jumped after the Food and Drug Administration (FDA) approved its messenger RNA (mRNA) flu shot. Those are not just news bites, they are a lesson in how markets treat narratives differently – capital raises for cyclical incumbents versus regulatory wins for biotechs. The clip matters because it shows why a company with deteriorating profits can still access markets and why a clinical win can send a battered revenue story soaring.